Litaba tsa mohala

Liteko tse Ncha tsa Clinical bakeng sa Acute Myeloid Leukemia

ngotsoeng ke mohlophisi

TC Biopharm (Holdings) PLC e phatlalalitse hore e amohetse MHRA le tumello ea Komiti ea Boitšoaro ea Lipatlisiso ho qala liteko tsa kliniki tsa kalafo ea lisele tsa gamma-delta tsa OmnImmune® bakeng sa kalafo ea Acute Myeloid Leukemia (AML).      

OmnImmune® an allogeneic unmodified cell therapy e nang le lisele tse kentsoeng le tse atolositsoeng tsa gamma delta T e se e fumane lebitso la setlhare sa likhutsana bakeng sa kalafo ea bakuli ba tšoeroeng ke mofetše oa mali le moko oa masapo. Liteko tsa Phase 2/3 li tla qala ho ingolisa halofong ea pele ea 2022 UK ka katoloso ho kena US kamora nakoana kamora moo.

"Re thabile haholo ho fumana tumello ea MHRA le ea Melao ea Boitšoaro ea Lipatlisiso, e tšoaeang mohato oa ho qetela oa ho fana ka protocol le ho qala ka ts'ebetso ea liteko tsa bongaka tsa kalafo ea rona ea AML," ho boletse Bryan Kobel, CEO oa TC BioPharm. "Ka mor'a ho phatlalatsa Phatlalatso ea Lithethefatsi tsa Likhutsana ho tsoa ho FDA, joale re bonts'itse bokhoni ba rona ba ho tsamaisa lits'ebetso tse tšoanang bakeng sa liteko tsa tleliniki Amerika le UK/EU. Liphetho tse ntle tse bontšitsoeng ke OmnImmune® litekong tsa bongaka tsa Phase 1b/2a lia khothatsa ebile li tiisa tumelo ea rona ea bokhoni ba eona ba ho ba kalafo e sebetsang bakeng sa Acute Myeloid Leukemia.

Litaba Tse Amanang

Mabapi le mongoli

mohlophisi

Mohlophisi e moholo oa eTurboNew ke Linda Hohnholz. O lula ntlong e kholo ea eTN e Honolulu, Hawaii.

Subscribe
Tsebiso ea
moeti
0 Comments
Li-feed tsa marang-rang
Sheba maikutlo ohle
0
Ke rata maikutlo a hau, ka kopo fana ka maikutlo.x
()
x
Arolelana ho...